Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00506402
Status:
COMPLETED
Last Update Posted:
2009-05-05
First Post:
2007-07-24
Brief Title:
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Sponsor:
CASI Pharmaceuticals Inc
Organization:
CASI Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None